| Literature DB >> 26362174 |
Michael Marks1, Oriol Mitjà2, Lasse S Vestergaard3, Allan Pillay4, Sascha Knauf5, Cheng-Yen Chen4, Quique Bassat6, Diana L Martin7, David Fegan8, Fasihah Taleo9, Jacob Kool10, Sheila Lukehart11, Paul M Emerson12, Anthony W Solomon13, Tun Ye14, Ronald C Ballard14, David C W Mabey15, Kingsley B Asiedu16.
Abstract
Yaws is endemic in west Africa, southeast Asia, and the Pacific region. To eradicate yaws by 2020, WHO has launched a campaign of mass treatment with azithromycin. Progress has been made towards achievement of this ambitious goal, including the validation of point-of-care and molecular diagnostic tests and piloting of the strategy in several countries, including Ghana, Vanuatu, and Papua New Guinea. Gaps in knowledge need to be addressed to allow refinement of the eradication strategy. Studies exploring determinants of the spatial distribution of yaws are needed to help with the completion of baseline mapping. The finding that Haemophilus ducreyi causes lesions similar to yaws is particularly important and further work is needed to assess the effect of azithromycin on these lesions. The integration of diagnostic tests into different stages of the eradication campaign needs investigation. Finally, studies must be done to inform the optimum mass-treatment strategy for sustainable interruption of transmission.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26362174 PMCID: PMC4668588 DOI: 10.1016/S1473-3099(15)00136-X
Source DB: PubMed Journal: Lancet Infect Dis ISSN: 1473-3099 Impact factor: 25.071